EMA grants marketing authorization to Myalepta for leptin deficiency
The European Medicines Agency (EMA)s Committee for Medicinal Products for Human Use (CHMP) has recommended granting of marketing authorization for Myalepta indicated for the treatment of complications of leptin deficiency in patients with generalized or partial lipodystrophy which is often associated with severe metabolic abnormalities, including hypertriglyceridemia, insulin resistance and/or diabetes. Myalepta, which is a recombinant human leptin analog, will be available as an 11.3 mg pow
To continue reading this article
Continue reading your article with a Emedinexus account..